Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-49122944 in healthy male subjects
NCT02280018Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JNJ-49122944 in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Nov 2014; status: completed.
02
Drugs
JNJ-49122944
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02280018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02280018.